Overview

Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases

Status:
Active, not recruiting

Trial end date:
2025-02-28

Target enrollment:

Participant gender:

Summary

This is a phase I dose escalation study (3+3 design) with a dose expansion arm (12 patients) designed to evaluate safety of the combination of Tas-102 and radioembolization using Yttrium-90 (90Y) resin microspheres for patients with chemotherapy-refractory liver-dominant chemotherapy-refractory metastatic colorectal cancer (mCRC).

Phase:

Phase 1

Details

Lead Sponsor:

University of California, San Francisco

Collaborators:

Sirtex Medical
Taiho Pharmaceutical Co., Ltd.

Treatments:

Trifluridine